On April 15, 2025, Athira Pharma, Inc. was approved to transfer its stock listing from the Nasdaq Global Select Market to the Nasdaq Capital Market due to non-compliance with minimum bid price requirements, granting an additional 180-day period to regain compliance until October 13, 2025.